ABVX Abivax SA

DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'

DGAP-News: ABIVAX / Key word(s): Annual Results
Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'

25.05.2020 / 18:00
The issuer is solely responsible for the content of this announcement.


Abivax publishes universal registration document 2020
"Document d'Enregistrement Universel"


PARIS, France May 25, 2020 - 06:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today the publication of its 2020 Universal Registration Document (Document d'Enregistrement Universel 2020), filed with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), on May 25, 2020.

The Registration Document includes the 2019 Annual Report, the corporate governance report prepared by the Board of Directors, and the conclusions of the statutory auditors.

Copies of the document are available free of charge at the Abivax headquarters on 5, rue de la Baume, 75008 Paris as well as in electronic form via the website of both Abivax () and the French Financial Market Authorities (). An English translation of the universal registration document will be available on June 30, 2020 at the latest.

******

About Abivax
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.
More information on the company is available at . Follow us on Twitter @ABIVAX_.


Contacts

Abivax
Finance
Didier Blondel

41
Abivax
Communications
Regina Jehle

63
Investors
LifeSci Advisors
Chris Maggos

Press Relations & Investors Europe
MC Services AG
Anne Hennecke

22
Public Relations France
Actifin
Ghislaine Gasparetto

22
Public Relations USA
Rooney Partners LLC
Marion Janic



25.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


1054839  25.05.2020 

fncls.ssp?fn=show_t_gif&application_id=1054839&application_name=news&site_id=research_pool
EN
25/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

Abivax: 1 director

A director at Abivax sold after exercising options/sold 1,104,640 shares at 54.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

Martial Descoutures
  • Martial Descoutures

Abivax : A well-deserved success, Outperform confirmed

We are significantly raising our TP from € 24 to € 88 following the positive results of the phase 3 induction trial (ABTECT) for obefazimod in ulcerative colitis. Obefazimod achieved significant clinical remission rates higher than those observed in phase 2b, and comparable to the best agents under development. Based on these results, we believe that Abivax is a credible M&A target for a pharma player looking to strengthen its position in immunology. Outperform rating reiterated.

Martial Descoutures
  • Martial Descoutures

Abivax : Un succès bien mérité, Surperformance confirmée

Nous relevons significativement notre OC de 24 € à 88 € suite aux résultats positifs de la phase 3 (ABTECT) en induction d’obefazimod dans la rectocolite hémorragique. Obefazimod a atteint des taux de rémission clinique significatifs supérieurs à ceux observés en phase 2b, et comparables aux meilleurs agents en développement. Suite à ces résultats, nous croyons qu’Abivax est une cible crédible d’acquisition pour une Pharma voulant se renforcer en Immunologie. Recommandation Surperformance réitér...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch